Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Savolitinib Approved in China for METex14+ NSCLC

June 23rd 2021

Savolitinib has been granted a conditional approval in China for use in patients with non–small cell lung cancer with MET exon 14 skipping alterations who experienced disease progression after previous systemic therapy or are unable to receive chemotherapy.

MET Inhibitors Find Their Niche in NSCLC

June 23rd 2021

Three-quarters of all cases of lung adenocarcinoma, the most common type of non–small cell lung cancer, are defined by oncogenic driver events involving receptor tyrosine kinase–orchestrated cellular signaling pathways.

Dr. Spira on the Updated Results of the CHRYSALIS Trial in EGFR-Mutant NSCLC

June 22nd 2021

Alexander Spira, MD, PhD, FACP, discusses the updated results of the phase 1 CHRYSALIS trial in EGFR-mutant non–small cell lung cancer.

Dr. Liu on the Rationale for the ARROW Trial in RET Fusion+ NSCLC

June 22nd 2021

Stephen Liu, MD, discusses the rationale for the ongoing phase 1/2 ARROW trial in RET fusion–positive non–small cell lung cancer.

Dr. Pennell on Understanding the Cost-Effectiveness of Osimertinib in NSCLC

June 22nd 2021

Nathan A. Pennell, MD, PhD, discusses the importance of understanding the cost-effectiveness of osimertinib in non–small cell lung cancer.

Experts Break Down Exciting Breakthroughs in NSCLC

June 22nd 2021

Experts in lung cancer discuss advances with targeted therapies in non–small cell lung cancer, highlighting the latest and most pivotal data in the thoracic space and how the data apply to clinical practice.

Garassino Highlights What’s In Store for Lung Cancer

June 21st 2021

Patients with lung cancer were identified as an at-risk group for developing severe complications as a result of SARS-CoV-2 infection, and thoracic oncologists were fast to respond with the establishment of the Thoracic Cancers International COVID-19 Collaboration.

Rapid Readouts: Updated Results and 5-Year Survival Outcomes From the PACIFIC Trial

June 18th 2021

David R. Spigel, MD, presents data from the 2021 American Society of Clinical Oncology annual meeting on the updated results from the phase 3 PACIFIC trial of durvalumab treatment after chemotherapy in patients with unresectable stage III non-small cell lung cancer

Frontline Sintilimab Plus Gemcitabine/Platinum Prolongs PFS in Squamous NSCLC

June 18th 2021

The addition of sintilimab to standard chemotherapy comprised of gemcitabine and platinum significantly improved progression-free survival with acceptable safety in previously untreated patients with advanced or metastatic squamous non–small cell lung cancer.

Clinical Implications of the ADAURA Trial

June 17th 2021

A panel of key opinion leaders in lung cancer considers the clinical implications of the ADAURA trial of adjuvant osimertinib and discuss how results may affect the treatment landscape in early stage NSCLC.

The ADAURA Trial of Adjuvant Osimertinib in NSCLC

June 17th 2021

Key opinion leader in lung cancer Solange Peters, MD, PhD, reviews safety and efficacy results from the ADAURA trial of adjuvant osimertinib in patients with stage IB-IIIA EGFR-mutated NSCLC following surgical resection.

ADAURA, Explosion of Targeted Agents Underscore Need for Molecular Testing in Lung Cancer

June 15th 2021

The data from the phase 3 ADAURA trial with adjuvant osimertinib are among the most significant to read out in the past year in the realm of non–small cell lung cancer.

ADCs Show Promise in NSCLC But Have a Long Road Ahead

June 14th 2021

The potential role for antibody-drug conjugates for treating patients with non–small cell lung cancer continues to evolve as new data challenge investigators to reexamine their approaches.

Adjuvant TKIs for Patients With EGFR-Mutated NSCLC

June 10th 2021

Christian Grohé, MD, comments on results of clinical trials studying EGFR-TKI combination regimens in NSCLC and highlights the need for composite end points that include quality of life and disease control.

Postoperative Radiotherapy in Resected Stage IIIA-N2 NSCLC

June 10th 2021

Expert panelists share insights on the results of the LUNG ART trial of postoperative radiotherapy in patients with resected stage IIIA-N2 disease and emphasize the risk for cardiac and pulmonary toxicity.

Dr. Ramalingam on Updated Data With Mobocertinib in EGFR Exon 20 Insertion+ NSCLC

June 8th 2021

Suresh S. Ramalingam, MD, FASCO, discusses updated data with mobocertinib in EGFR exon 20 insertion–positive advanced non–small cell lung cancer.

Nivolumab Plus Chemotherapy Outperforms Chemotherapy Alone in Resectable NSCLC

June 6th 2021

Neoadjuvant nivolumab in combination with platinum-doublet chemotherapy significantly improved pathological complete response rates and had a greater depth of pathological response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

Adjuvant Gefitinib Fails to Outshine Chemo in EGFR+ NSCLC

June 6th 2021

Adjuvant treatment with gefitinib delayed early relapse in patients with completely resected EGFR-mutant non–small cell lung cancer. However, the EGFR inhibitor did not significantly improve disease-free survival or overall survival compared with cisplatin/vinorelbine.

Lung Cancer and Leukemia Recap at ASCO 2021: Drs Ed Kim and Anthony Mato

June 6th 2021

OncLive sits down with Edward S. Kim, MD, and Anthony R. Mato, MD, on the pivotal studies in lung cancer and leukemia at the 2021 ASCO Annual Meeting.

Alectinib Fails to Improve OS in ALK-Positive NSCLC

June 5th 2021

In a final overall survival analysis of the J-ALEX study, patients with non-small cell lung cancer receiving alectinib failed to achieve better results than patients receiving crizotinib.